Abstract
Molnupiravir, EIDD-2801/MK-4482, the prodrug of the ribonucleoside analog ß-d-N4-hydroxycytidine (NHC), has activity against a number of RNA viruses including severe acute respiratory syndrome coronavirus 2, severe acute respiratory syndrome coronavirus, Middle East respiratory syndrome coronavirus, seasonal and pandemic influenza viruses, and respiratory syncytial virus.
Single and multiple doses of molnupiravir were evaluated in this first-in-human, phase 1, randomized, double-blind, placebo-controlled study in healthy volunteers, which included evaluation of the effect of food on pharmacokinetics.
EIDD-1931 appeared rapidly in plasma, with a median time of maximum observed concentration of 1.00 to 1.75 hours, and declined with a geometric half-life of approximately 1 hour, with a slower elimination phase apparent following multiple doses or higher single doses (7.1 hours at the highest dose tested). Mean maximum observed concentration and area under the concentration versus time curve increased in a dose-proportional manner, and there was no accumulation following multiple doses. When administered in a fed state, there was a decrease in the rate of absorption, but no decrease in overall exposure.
Molnupiravir was well tolerated. Fewer than half of subjects reported an adverse event, the incidence of adverse events was higher following administration of placebo, and 93.3% of adverse events were mild. One discontinued early due to rash. There were no serious adverse events and there were no clinically significant findings in clinical laboratory, vital signs, or electrocardiography. Plasma exposures exceeded expected efficacious doses based on scaling from animal models; therefore, dose escalations were discontinued before a maximum tolerated dose was reached.
Clinical trial identifier This study was registered at ClinicalTrials.gov with the identifier NCT04392219.
Competing Interest Statement
Ridgeback Biotherapeutics LP funded this study and has subsequently entered into a collaboration with Merck to jointly develop molnupiravir. Wendy Painter is an employee of Ridgeback Biotherapeutics LP and previously was a consultant to Emory Institute of Drug Development; Merribeth Morin and Laura Szewczyk are employees of Ridgeback Biotherapeutics; Wayne Holman is a co founder, owner, and advisor to Ridgeback Biotherapeutics; Firas Almazedi, Hamzah Malik, and Nicola Eraut are employees of Covance Clinical Research Unit Limited (the drug development division of Laboratory Corporation of America Holdings), which was responsible for the clinical conduct of this study; Jim Bush is an employee of Covance Clinical Research Unit Limited and is an equity holder of Laboratory Corporation of America Holdings; George Painter is the director of the Emory Institute of Drug Development, is the chief executive officer of Drug Innovation Ventures at Emory, and has a financial interest in molnupiravir.
Clinical Trial
NCT04392219
Funding Statement
Ridgeback Biotherapeutics LP funded this study and has subsequently entered into a collaboration with Merck to jointly develop molnupiravir.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
NHS Health Research Authority North East-York Research Ethics Committee, NHSBT Newcastle Blood Donor Centre, Holland Drive, Newcastle Upon Tyne, UK
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Not yet published.
